Calculate your SIP ReturnsExplore

O H L VOL


Days Range

Data is not available currently. Please check back later.

Data is not available currently. Please check back later.

About Sun Pharmaceuticals Industries

History

Sun Pharmaceutical Industries Ltd was incorporated in 1983 and began its operations in Kolkata with only 5 products to treat psychiatric ailments. They built a compact manufacturing facility for tablets/capsules at Vapi, Gujarat. An administrative office was opened in Mumbai in 1986. By 1987, they had been marketing their products nationwide. In the late 1980s, the company began exporting their products to neighbouring countries. In 1998, they established their first research centre, SPARC, to create a strong base for product development in the following years. In 1994, the company became listed via an IPO. In 2016, Sun Pharma and AstraZeneca Pharma India Ltd began a partnership for the distribution of an innovative Type 2 diabetes medicine named dapagliflozin in India. In the same year, Sun Pharma and the International Centre for Genetic Engineering and Biotechnology (ICGEB) also agreed to together develop a novel drug for dengue. During in 2021, Sun Pharma launched 96 products in the domestic market. It also supplied drugs like Remdesivir, Favipiravir, Hydroxychloroquine (HCQS), and Liposomal Amphotericin B for the treatment of COVID-19 as well as the anti-epileptic Brevipil (Brivaracetam) and FluGuard (Favipiravir).  

Business Segments

Sun Pharmaceutical Industries Ltd, along with its subsidiaries and associates, is the fourth largest generic pharma company. As of September 2023, the company has a robust global presence with 43 manufacturing facilities across the world. India and the US are two major markets, accounting for more than 60% of the company's revenue in FY 2023. They also have a strong presence in emerging markets such as Russia, Romania, South Africa, Brazil, Mexico, etc.  In terms of the share of disease-wise drugs in the total revenue from India in FY 2023, Cardiology solutions contribute 18%, Neuro-Psychiatry 16%, and Gastroenterology 12%, among others. The company manufactures a wide range of pharmaceutical formulations for chronic and acute therapies. This covers generics, complex products, antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates, among others. The portfolio is made of over 2,000 high-quality products with multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, ointments, etc.  Sun Pharmaceutical Industries invests around 7-8% of its global revenue every year in research. The R&D capabilities span the development of differentiated products, such as liposomal products, lyophilised injections, inhalers, and nasal sprays, alongside controlled-release dosage forms. Some of the subsidiaries of Sun Pharmaceuticals include Sun Pharma Laboratories Limited, Sun Pharma Holdings, Sun Pharma Distributors Limited, among others.

Key Personnel

Dilip Shanghvi, Founder and Managing Director Mr. Shanghvi is the founder of Sun Pharmaceutical Industries Ltd. with extensive experience in the pharmaceutical industry. Starting out as a first-generation entrepreneur, Mr. Shanghvi is today also the Chairman of Sun Pharma Advanced Research Company Ltd and of the Shantilal Shanghvi Foundation. 

Corporate Actions

Bonus Shares Sun Pharmaceuticals has issued bonus shares once in 2013 at a ratio of 1:1. Stock Split The face value of the stock had been split once in 2010, from ₹5 to ₹1. Buyback  The company performed a buyback of shares in July 2016. Mergers and Acquisitions
  • In FY 2023, Sun Pharma acquired Concert Pharma. Inc. which was developing a treatment for Alopecia Areata.
  • Since 2012, the company has acquired 6 companies in order to scale up their operations. Their past acquisitions include Dusa Pharma, Taro Pharma, URL Pharma, Ranbaxy Laboratories, Biosintez and Pola Pharma.

Management Outlook

The management expects global pharmaceutical spending to grow by a CAGR of 3-6% between 2023 and 2027 to reach a total market size of roughly US$ 1.9 trillion. The company also expects the global specialty pharmaceutical solutions market to grow. It already commands 43% of the total pharmaceutical spending globally as of 2022 and is expected to grow to 56% by 2027. Sensing the above shifts, Sun Pharma has continued to expand its global specialty offerings, with a focus on the areas of dermatology, ophthalmology and onco-dermatology. Their investments are designed to acquire products through in-licensing/acquisitions and in-house R&D and build front-end commercial infrastructure for these products.

Parent Organisation
Sun Pharma
Managing Director
None
Founded
1993
NSE Symbol
SUNPHARMA

Peer Comparision

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)

Community Discussion

A
AngelOne
10th July 2024
0 Likes
0 Replies

A
AngelOne
10th July 2024
Sun Pharmaceuticals Industries Ltd-latest-market-updates-15080
0 Likes
0 Replies

Sun Pharmaceutical Industries Ltd FAQs

Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price as of July 22, 2024, on NSE is Rs 1587.35 (NSE) and Rs 1587.35 (BSE) on BSE.
Yes, You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share can be bought through the following modes:
1. Direct investment: You can buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares.
The promoters of Sunpharma are Shanghvi Finance Private Limited, Dilip.S.Shanghvi, Dilip Shantilal Shanghvi, Aditya Medisales Limited, Raksha S.Valia and Sudhir V. Valia.
Sunpharma provides a range of over-the-counter (OTC)/consumer healthcare products.
Being a maker of over-the-counter (OTC)/consumer healthcare products including Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics). These are a few of their flagship OTC brands that are marketed globally.
Open Free Demat Account!

Enjoy Zero Brokerage on Equity Delivery

Join our 2 Cr+ happy customers

+91
Top Stocks

VIEW ALLView All Stocks

Top Gainers





VIEW ALLView All Stocks

Top Losers





VIEW ALLView All Stocks

Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy Zero Brokerage on Equity Delivery

Get the link to download the App

Send App Link
Open Free Demat Account!
Enjoy Zero Brokerage on Stock Investments.